调节性T细胞在自体干细胞动员和移植过程中抑制骨髓瘤特异性免疫
该临床前研究显示,患者动员干细胞移植物含大量效应CD8 T细胞和免疫抑制性调节性T细胞(Tregs),骨髓驻留T细胞在干细胞动员(SCM)期间被有效动员;在临床前骨髓瘤模型中,SCM期间严格去除Treg可产生含多能CD8 T效应记忆细胞的移植物并显著增强移植后骨髓瘤控制;合成IL-2/IL-15模拟物可选择性扩增CD8 T细胞并保护受体免于骨髓瘤进展。
要点
- 患者动员干细胞移植物含高数量效应CD8 T细胞和免疫抑制性Tregs。
- 临床前模型中SCM期间去除Treg可增强移植后骨髓瘤控制。
- 合成IL-2/IL-15模拟物可扩增移植物中多能CD8 T细胞并保护受体。
核心结论
- SCM期间去除Treg可减轻对肿瘤免疫的约束并在ASCT后实现深度骨髓瘤控制。
- 直接选择性细胞因子信号作用于CD8 T细胞可重现该效应,代表一种可临床测试的策略以改善ASCT后反应。
研究设计与样本
- 临床前骨髓瘤模型研究,在SCM期间进行或不进行严格Treg去除后行ASCT。
- 探索临床可转化的转化方法,包括抗体为基础的方法和合成IL-2/IL-15模拟物。
主要发现
- 患者动员干细胞移植物含高数量效应CD8 T细胞和免疫抑制性Tregs。
- 骨髓驻留T细胞在SCM期间被有效动员。
- SCM期间Treg去除产生含多能CD8 T效应记忆细胞的移植物,并显著增强ASCT后骨髓瘤控制。
- 抗体为基础的方法仅导致部分Treg去除,不足以重现该效应。
- 合成IL-2/IL-15模拟物刺激CD8 T细胞上的IL-2受体而不结合Treg使用的高亲和力IL-2Ra,有效扩增动员移植物中多能CD8 T细胞并保护受体免于ASCT后骨髓瘤进展。
临床怎么用
- 作者认为直接选择性细胞因子信号作用于CD8 T细胞可重现Treg去除效应,代表一种可临床测试的策略以改善ASCT后反应。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autologous stem cell transplantation (ASCT) is the standard of care consolidation therapy for eligible patients with myeloma but most patients eventually progress, an event associated with features of immune escape. Novel approaches to enhance antimyeloma immunity after ASCT represent a major unmet need. Here, we demonstrate that patient-mobilized stem cell grafts contain high numbers of effector CD8 T cells and immunosuppressive regulatory T cells (Tregs). We showed that bone marrow (BM)-residing T cells are efficiently mobilized during stem cell mobilization (SCM) and hypothesized that mobilized and highly suppressive BM-derived Tregs might limit antimyeloma immunity during SCM. Thus, we performed ASCT in a preclinical myeloma model with or without stringent Treg depletion during SCM. Treg depletion generated SCM grafts containing polyfunctional CD8 T effector memory cells, which dramatically enhanced myeloma control after ASCT. Thus, we explored clinically tractable translational approaches to mimic this scenario. Antibody-based approaches resulted in only partial Treg depletion and were inadequate to recapitulate this effect. In contrast, a synthetic interleukin-2 (IL-2)/IL-15 mimetic that stimulates the IL-2 receptor on CD8 T cells without binding to the high-affinity IL-2Ra used by Tregs efficiently expanded polyfunctional CD8 T cells in mobilized grafts and protected recipients from myeloma progression after ASCT. We confirmed that Treg depletion during stem cell mobilization can mitigate constraints on tumor immunity and result in profound myeloma control after ASCT. Direct and selective cytokine signaling of CD8 T cells can recapitulate this effect and represent a clinically testable strategy to improve responses after ASCT.
引用
- Takahashi S, Minnie SA, Ensbey KS, et al. Regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation. Blood. 2024. PMID: 38295333. doi:10.1182/blood.2023022000
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。